Update in Diagnosis and Management of Primary Immunodeficiency Disease
Professional Medical Education Program
Saturday, June 29, 2013
Hilton Baltimore, Baltimore, MD
9:00 am – 5:00 pm
(Pre-registration is required)
The Clinical Immunology Society (CIS) and the Immune Deficiency Foundation (IDF) invite you to attend the Update in Diagnosis and Management of Primary Immunodeficiency Disease.
To increase early diagnosis and proper treatment of patients with primary immunodeficiency diseases as physicians need to be educated about the recognition and disease management of primary immunodeficiencies. Since individuals are most likely to first contact their primary care providers with symptoms, these physicians especially need information about how to meet their patients’ needs with proper diagnosis, treatments and referrals. In addition, immunologists, allergists and others who treat primary immunodeficiency diseases need to be updated on matters that will lead to earlier diagnosis and appropriate treatment modalities. Nurses who care for patients with primary immunodeficiency diseases or administer immune globulin replacement treatment need continuing education in order to improve the quality of care they provide.
This program is designed for immunologists, allergists, nursing professionals specializing in immunology and other professionals who treat primary immunodeficiency disease. Primary care physicians, including family practitioners and pediatricians will benefit from the program and are encouraged to attend.
Topics to be covered include:
- Immune System Basics for Primary Immunodeficiency Disease (PIDD)
- Clinical Presentations and Lab tests to run for diagnosing PIDD
- Therapies: Treatment of PIDD through Bone Marrow Transplantation, Immune Globulin Replacement and Gene Therapy
- Case studies for PIDD
- Co-managing PIDD Patients and Questions & Answers
- Describe the epidemiology of primary immunodeficiency diseases and recognize the ways in which patients present clinically;
- Identify the laboratory approaches to assess humoral, cellular, and innate immune function and recognize the current limitations of laboratory testing;
- Explain that primary immunodeficiency can present with a wide variety of symptoms (infections, autoimmune/inflammatory disorders and part of a syndrome complex);
- Recognize that Common Variable Immunodeficiency can present at any age and often does later in life;
- Report the various sources of stem cells that can be used for immune reconstitution of patients with primary immunodeficiency diseases as well as differentiate between the advantages and disadvantages of the various types of stem cell transplantation in various primary immunodeficiency diseases;
- Define the various routes for the administration of immune globulin including IVIG and SCIG;
- Identify and treat adverse reactions, categorize the new safety measures and develop an IVIG or SCIG management plan.
This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint-sponsorship of the Clinical Immunology Society (CIS) and Immune Deficiency Foundation (IDF). The CIS is accredited by the ACCME to provide continuing medical education for physicians.
The Clinical Immunology Society (CIS) designates this live activity for a maximum of 6.5 AMA PRA Category 1 Credit(s) ™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
You are also welcome to register for all activities, sessions and meals functions of the IDF 2013 National Conference, June 27-29, 2013. If you would like to register for both the Professional Education Program and the IDF 2013 National Conference, please check the appropriate box on the online registration form.
Pre-registration is requested, but walk-ins will be accepted on a first-come, first-served basis. Please understand telephone registrations cannot be accepted.
Pre-Registration Deadline: May 18, 2013
Registration Cancellation Deadline: May 31, 2013